Home » Stocks » SGMO

Sangamo Therapeutics, Inc. (SGMO)

Stock Price: $10.12 USD 0.35 (3.58%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $10.15 +0.03 (0.30%) Nov 27, 4:44 PM

Stock Price Chart

Key Info

Market Cap 1.43B
Revenue (ttm) 147.24M
Net Income (ttm) -75.84M
Shares Out 141.44M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $10.12
Previous Close $9.77
Change ($) 0.35
Change (%) 3.58%
Day's Open 9.81
Day's Range 9.81 - 10.13
Day's Volume 1,103,064
52-Week Range 4.81 - 13.20

More Stats

Market Cap 1.43B
Enterprise Value 819.31M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 141.44M
Float n/a
EPS (basic) -0.59
EPS (diluted) -0.59
FCF / Share 0.96
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 9.49%
Payout Ratio n/a
Shares Short 20.37M
Short Ratio 13.86
Short % of Float n/a
Beta 2.04
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 10.53
PS Ratio 9.72
PB Ratio 2.65
Revenue 147.24M
Operating Income -84.65M
Net Income -75.84M
Free Cash Flow 135.87M
Net Cash 612.07M
Net Cash / Share 4.33
Gross Margin -29.54%
Operating Margin -57.49%
Profit Margin -51.50%
FCF Margin 92.28%
ROA -6.60%
ROE -16.16%
ROIC -18.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (9)

Buy 6
Overweight 0
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.43*
(111.76% upside)
Low
12.0
Current: $10.12
High
36.0
Target: 21.43
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue10284.4536.5719.3939.5445.8724.1321.6610.3220.81
Revenue Growth21.29%130.95%88.6%-50.96%-13.8%90.07%11.44%109.86%-50.4%-
Gross Profit10284.4536.5719.3939.5445.8724.1321.6610.3220.81
Operating Income-105-77.15-56.36-72.56-46.86-26.78-26.71-22.20-35.82-24.94
Net Income-95.19-68.33-54.57-71.66-40.70-26.42-26.62-22.26-35.75-24.85
Shares Outstanding11296.9478.0870.5569.7667.0255.9752.7450.5145.17
Earnings Per Share-0.85-0.70-0.70-1.02-0.58-0.39-0.48-0.42-0.71-0.55
Operating Cash Flow-14436.5511.18-65.88-33.72-5.68-19.48-8.08-25.90-23.93
Capital Expenditures-20.68-43.07-3.75-0.73---0.43-0.72-0.58-0.70
Free Cash Flow-165-6.527.43-66.62-33.72-5.68-19.91-8.81-26.47-24.63
Cash & Equivalents36240024314320917993.1363.5584.1360.29
Total Debt41.1927.69--------
Net Cash / Debt32137224314320917993.1363.5584.1360.29
Assets63859028715821724314182.5387.3463.00
Liabilities20522398.8421.7024.8036.5819.1317.647.207.09
Book Value43336718813619220712264.9080.1355.91
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sangamo Therapeutics, Inc.
Country United States
Employees 354
CEO Alexander D. Macrae

Stock Information

Ticker Symbol SGMO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SGMO
IPO Date April 6, 2000

Description

Sangamo Therapeutics, a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression. Its therapeutic products that are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; ST-920 gene therapy for Fabry disease; ST-101 gene therapy for phenylketonuria; ST-400 and BIVV-003 for the treatment of hemoglobinopathies; SB-913 for the treatment of Mucopolysaccharidosis type II; SB-318 for the treatment of Mucopolysaccharidosis type I; and SB-FIX for the treatment of hemophilia B. The company has collaborative and strategic partnerships with Biogen Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.